EUVIMEDEUVIMED entdecken
VergleichsstudieÜbersichtsarbeit

Enoxaparin 40 mg Twice Daily With Peak Anti-Xa Adjustments Is Safe and Necessary to Achieve Therapeutic Chemoprophylaxis in Burn-Injured Patients

Desiree N Pinto iD, Sophia Lee iD, Cory Johnson iD, Rola Halabi iD, Tuan D Le iD, Lauren T Moffatt, Bonnie C Carney iD, Shane K Mathew iD, Melissa McLawhorn iD, Shawn Tejiram, Taryn E Travis iD, Jeffrey W Shupp

Journal of Burn Care & Research · 2025

DOI: 10.1093/jbcr/irae201 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Burn Care & Research, 2025. Verfasst von Desiree N Pinto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Firefighters' Burn and Surgical Research Laboratory, MedStar Health Research Institute, Washington, DC, United States. Hauptthemen laut MEDLINE: Enoxaparin, Burns, Venous Thromboembolism, Hemorrhage. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Burn injury results in hypercoagulability and an increased venous thromboembolism risk. However, the most effective chemoprophylaxis for burn-injured patients has yet to be elucidated. Therefore, this study aims to identify the safety and efficacy of a burn center’s venous thromboembolism protocol modification, which increased the dose of enoxaparin from 40 mg daily to 40mg twice daily with peak anti-Xa level adjustments. It was hypothesized that this change would not increase bleeding complications and would decrease venous thromboembolism rates. All adult, burn-injured patients admitted to a regional burn center were retrospectively reviewed 1 year before and after the implementation of this protocol modification. There were no differences in demographics, injury characteristics, or hospital length of stay between the pre- (n = 432) and postprotocol modification (n = 407) groups. Bleeding complications did not increase in the postprotocol group, including intraoperative blood loss (50 vs 25cc), the total number of transfusions (9.0 vs 6.0 units), and GI bleeding events (0.7 vs 0.2%) (all P > .05). Most patients receiving enoxaparin 40 mg twice daily achieved an initial therapeutic level based on peak anti-Xa measurements (46.5%), yet the rate of venous thromboembolisms between pre- and postprotocol groups was not statistically different (1.4 vs 0.7%, P = .5072). Factors associated with an initial sub- or supratherapeutic peak anti-Xa level were percent total body surface area, weight, body mass index, and creatinine clearance. Overall, this study demonstrated that a higher dose of enoxaparin (40 mg twice daily) with peak anti-Xa level adjustments was safe in burn-injured patients and necessary to obtain therapeutic levels of chemoprophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EnoxaparinBurnsVenous ThromboembolismHemorrhageAnticoagulantsBlood CoagulationRetrospective StudiesBurn UnitsDrug Administration ScheduleDose-Response Relationship, DrugHumansMaleFemaleAdultMiddle Aged

Stichwörter der Autor:innen

anti-Xa levelsbleeding complicationsenoxaparinvenous thromboembolism

Substanzen

EnoxaparinAnticoagulants

Autor:innen und Institutionen

  • Firefighters' Burn and Surgical Research Laboratory, MedStar Health Research Institute, Washington, DC, United States.
  • Department of Surgery, Georgetown University School of Medicine, Washington, DC, United States.
  • Department of Pharmacy, MedStar Washington Hospital Center, Washington, DC, United States.
  • The Burn Center, Department of Surgery, MedStar Washington Hospital Center, Washington, DC, United States.
  • Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC, United States.
  • Department of Plastic and Reconstructive Surgery, Georgetown University School of Medicine, Washington, DC, United States.

ORCID-Profile: Desiree N Pinto, Sophia Lee, Cory Johnson, Rola Halabi, Tuan D Le, Bonnie C Carney, Shane K Mathew, Melissa McLawhorn, Taryn E Travis

Zitieren

APA

Pinto, D. N., Lee, S., Johnson, C., Halabi, R., Le, T. D., Moffatt, L. T., Carney, B. C., Mathew, S. K., McLawhorn, M., Tejiram, S., Travis, T. E., & Shupp, J. W. (2025). Enoxaparin 40 mg Twice Daily With Peak Anti-Xa Adjustments Is Safe and Necessary to Achieve Therapeutic Chemoprophylaxis in Burn-Injured Patients. Journal of Burn Care & Research. https://doi.org/10.1093/jbcr/irae201

Vancouver

Pinto DN, Lee S, Johnson C, Halabi R, Le TD, Moffatt LT, et al. Enoxaparin 40 mg Twice Daily With Peak Anti-Xa Adjustments Is Safe and Necessary to Achieve Therapeutic Chemoprophylaxis in Burn-Injured Patients. Journal of Burn Care & Research. 2025. doi:10.1093/jbcr/irae201

BibTeX
@article{Pinto2025,
  author = {Pinto, Desiree N and Lee, Sophia and Johnson, Cory and Halabi, Rola and Le, Tuan D and Moffatt, Lauren T and Carney, Bonnie C and Mathew, Shane K and McLawhorn, Melissa and Tejiram, Shawn and Travis, Taryn E and Shupp, Jeffrey W},
  title = {Enoxaparin 40 mg Twice Daily With Peak Anti-Xa Adjustments Is Safe and Necessary to Achieve Therapeutic Chemoprophylaxis in Burn-Injured Patients},
  journal = {Journal of Burn Care & Research},
  year = {2025},
  doi = {10.1093/jbcr/irae201}
}
Kostenlos starten →